JAMA Network Home
Sign In
Original Investigation

Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration

JAMA Ophthalmology 10.1001/jamaophthalmol.2025.3821

October 23, 2025 at 11:00 AM EDT

Read the full article

What is the association of glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development or progression of age-related macular degeneration (AMD) compared with other weight loss drugs for patients with overweight or obesity?In this cohort study of 91 408 patients, GLP-1RA use was associated with a reduced risk of developing nonexudative AMD but showed no association with progression to exudative AMD.These findings suggest that GLP-1RAs may offer ocular benefits compared with other weight loss drugs, supporting further investigation in prospective, randomized studies.

Corresponding Author: Benjamin K. Young, MD, MS, Department of Ophthalmology, Casey Eye Institute, Oregon Health youngbe@ohsu.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2025.3821?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102325

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks